FDA approves obinutuzumab as CLL "breakthrough"
Added: Friday 29 November 2013
The US Food and Drug Administration (FDA) has approved the drug obinutuzumab for chronic lymphocytic leukaemia. According to an FDA statement, this will be the first drug to be approved with a "breakthrough therapy designation". It is a monoclonal antibody administered intravenously.
In order to be able to see the content from the www.medscape.com pages, please create first a free account at following link: